The obesity epidemic has been a growing concern for years, with rising rates and a lack of effective treatments. Fortunately, medical researchers have developed an injectable medication for diabetes and obesity: terzepatite (Mounjaro).
This medication is expected to revolutionize medical treatment for obesity and is pending approval from the FDA in the near future.
Current FDA-Approved Weight Loss Medications
- Phentermine, which was first available in the 1950s, produces an average weight loss of 5% body weight. When combined with topiramate (a migraine medication), it can produce 8-10% average weight loss.
- Contrave, a combination of bupropion (an antidepressant) and naltrexone (an addiction prevention medication), produces 4-5% average weight loss.
- Saxenda was the first approved injectable weight loss medication that leads to 8% average weight loss after its 2014 approval by the FDA.
- Wegovi (cemagletide) was the next approved drug that produced 15% average weight loss after one year with weekly injections.
How Does Terzepatite (Mounjaro) Work?
Terzepatite targets both GLP1 receptor to boost GLP levels as well as GIP receptor where their actions are synergistic in order to promote greater overall weight loss than previously seen medications.
The Surmount trial established terzepatites efficacy with 2539 participants receiving either placebo or 5 mg/ 10 mg/15 mg doses of terzetapitide over 72 weeks resulting in 3%, 15%, 19%, 20.9% respectively in terms of average bodyweight losses when compared to placebo treatment alone..
Administration & Side Effects
Terzetapitide is taken once weekly via injection using pre-filled pens with no visible needles involved; side effects experienced during dose escalation periods are mainly gastrointestinal such as nausea, diarrhea or constipation but are typically mild and transient in nature.
Who Could Benefit From Terzetapitide?
Once approved by the FDA for treatment of obesity; adults with BMI >30 or >27 plus other obesity related conditions such as diabetes, high blood pressure, high cholesterol or sleep apnea may be good candidates for this therapy should they be willing to commit to weekly injections long term due to relapsing nature of obesity condition itself.
Those suffering from both diabetes & obesity might especially benefit since terzetapitide could potentially replace certain diabetes medications that may cause patients’ body weights gain instead – insulin for instance .
Cost Considerations & Support Needed
Wegovi’s initial enthusiasm was dampened by its cost – roughly $1000 per month out-of pocket – so we anticipate similar situation with Terzeptaitde too.
Therefore making comprehensive programs offered by physician trained in treating obese conditions accompanied by adequate nutrition support & structured exercise regimen critical components towards ensuring success when taking this medication long term due to chronicity & relapsing nature associated with obesity itself .
Newer class drugs like Terzeptaitde have brought about much needed hope after years without progress in combating obesity ; alongside less invasive procedures these medications provide multiple effective options against bariatric surgery even though insurers often view treating obese patients as an issue solely relying on willpower rather than acknowledging it as a disease thus hindering accessibilities .
The health benefits outweigh costs associated however , leading towards improved health outcomes while decreasing health care costs at same time .